Annual report pursuant to Section 13 and 15(d)

Subsequent Events - Additional Information (Detail)

v3.3.1.900
Subsequent Events - Additional Information (Detail)
 12 Months Ended
Mar. 07, 2016
Patient
Jan. 01, 2016
shares
Jan. 02, 2015
shares
Dec. 31, 2015
shares
Subsequent Event [Line Items]        
Description of phase 2 study plans in SLE       The Phase 2 trial will test the efficacy, safety, tolerability and biologic effects of Resunab as a novel, non-immunosuppressive oral treatment to improve signs and symptoms of SLE. The study plans to enroll 100 adult SLE patients with active musculoskeletal disease and will be carried out at approximately ten sites in the United States. These patients will receive either placebo or three different doses of Resunab daily for 84 days with 28 days follow-up.
Subsequent Event [Member]        
Subsequent Event [Line Items]        
Number of SLE adult patients enrolled under phase 2 clinical study plan | Patient 100      
2014 Incentive Plan [Member]        
Subsequent Event [Line Items]        
Shares available for grant       4,545,135
Increases in number of shares of common stock available for issuance, minimum percentage of outstanding common stock       7.00%
Increase in number of shares of common stock available for issuance     1,815,683  
2014 Incentive Plan [Member] | Subsequent Event [Member]        
Subsequent Event [Line Items]        
Total shares reserved, stock option plan   9,916,017    
Shares available for grant   5,795,133    
Increase in number of shares of common stock available for issuance   1,250,000